+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epilepsy Therapeutic Market in APAC 2024-2028

  • PDF Icon

    Report

  • 156 Pages
  • January 2024
  • Region: Asia Pacific
  • TechNavio
  • ID: 5143022
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The epilepsy therapeutic market in APAC is forecasted to grow by USD 449.35 mn during 2023-2028, accelerating at a CAGR of 4.19% during the forecast period. The report on the epilepsy therapeutic market in APAC provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet need for disease-modifying treatment, increase in patient population having epilepsy, and rising awareness regarding epilepsy.

The epilepsy therapeutic market in APAC is segmented as below:

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

By Product

  • First-generation epilepsy therapeutics
  • Second-generation epilepsy therapeutics
  • Third-generation epilepsy therapeutics

This study identifies the reformation of marketed epilepsy drugs as one of the prime reasons driving the epilepsy therapeutic market in APAC growth during the next few years. Also, the emergence of new-generation AEDS and AEDS with novel mechanism action will lead to sizable demand in the market.

The report on the epilepsy therapeutic market in APAC covers the following areas:

  • Epilepsy therapeutic market in APAC sizing
  • Epilepsy therapeutic market in APAC forecast
  • Epilepsy therapeutic market in APAC industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy therapeutic market in APAC vendors that include Alkem Laboratories Ltd., Bausch Health Companies Inc., BIAL, Dr Reddys Laboratories Ltd., Eisai Co. Ltd., H Lundbeck AS, Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, SK Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and GlaxoSmithKline Plc. Also, the epilepsy therapeutic market in APAC analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Country Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on APAC - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on APAC: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
4 Historic Market Size
4.1 epilepsy therapeutics market in APAC 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on epilepsy therapeutics market in APAC 2018 - 2022 ($ million)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.3 Product Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 22: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 23: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 24: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 25: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 26: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 27: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 28: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Distribution Channel
6.1 Market segments
Exhibit 29: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 30: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 31: Chart on Comparison by Distribution Channel
Exhibit 32: Data Table on Comparison by Distribution Channel
6.3 Hospital pharmacy - Market size and forecast 2023-2028
Exhibit 33: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 34: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 36: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
6.4 Retail pharmacy - Market size and forecast 2023-2028
Exhibit 37: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 38: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 40: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
6.5 Online pharmacy - Market size and forecast 2023-2028
Exhibit 41: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 42: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 44: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 45: Market opportunity by Distribution Channel ($ million)
Exhibit 46: Data Table on Market opportunity by Distribution Channel ($ million)
7 Market Segmentation by Product
7.1 Market segments
Exhibit 47: Chart on Product - Market share 2023-2028 (%)
Exhibit 48: Data Table on Product - Market share 2023-2028 (%)
7.2 Comparison by Product
Exhibit 49: Chart on Comparison by Product
Exhibit 50: Data Table on Comparison by Product
7.3 First-generation epilepsy therapeutics - Market size and forecast 2023-2028
Exhibit 51: Chart on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibit 52: Data Table on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Chart on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibit 54: Data Table on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
7.4 Second-generation epilepsy therapeutics - Market size and forecast 2023-2028
Exhibit 55: Chart on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibit 56: Data Table on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Chart on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibit 58: Data Table on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
7.5 Third-generation epilepsy therapeutics - Market size and forecast 2023-2028
Exhibit 59: Chart on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibit 60: Data Table on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Chart on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibit 62: Data Table on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Product
Exhibit 63: Market opportunity by Product ($ million)
Exhibit 64: Data Table on Market opportunity by Product ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 65: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 66: Chart on Market share By Geographical Landscape - 2023-2028 (%)
Exhibit 67: Data Table on Market share By Geographical Landscape - 2023-2028 (%)
9.2 Geographic comparison
Exhibit 68: Chart on Geographic comparison
Exhibit 69: Data Table on Geographic comparison
9.3 China - Market size and forecast 2023-2028
Exhibit 70: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 71: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 73: Data Table on China - Year-over-year growth 2023-2028 (%)
9.4 Japan - Market size and forecast 2023-2028
Exhibit 74: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 75: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 77: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.5 India - Market size and forecast 2023-2028
Exhibit 78: Chart on India - Market size and forecast 2023-2028 ($ million)
Exhibit 79: Data Table on India - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibit 81: Data Table on India - Year-over-year growth 2023-2028 (%)
9.6 Australia - Market size and forecast 2023-2028
Exhibit 82: Chart on Australia - Market size and forecast 2023-2028 ($ million)
Exhibit 83: Data Table on Australia - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Chart on Australia - Year-over-year growth 2023-2028 (%)
Exhibit 85: Data Table on Australia - Year-over-year growth 2023-2028 (%)
9.7 Rest of APAC - Market size and forecast 2023-2028
Exhibit 86: Chart on Rest of APAC - Market size and forecast 2023-2028 ($ million)
Exhibit 87: Data Table on Rest of APAC - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Chart on Rest of APAC - Year-over-year growth 2023-2028 (%)
Exhibit 89: Data Table on Rest of APAC - Year-over-year growth 2023-2028 (%)
9.8 Market opportunity By Geographical Landscape
Exhibit 90: Market opportunity By Geographical Landscape ($ million)
Exhibit 91: Data Table on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 92: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 93: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 94: Overview on factors of disruption
11.4 Industry risks
Exhibit 95: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 96: Vendors covered
12.2 Market positioning of vendors
Exhibit 97: Matrix on vendor position and classification
12.3 Bausch Health Companies Inc.
Exhibit 98: Bausch Health Companies Inc. - Overview
Exhibit 99: Bausch Health Companies Inc. - Business segments
Exhibit 100: Bausch Health Companies Inc. - Key news
Exhibit 101: Bausch Health Companies Inc. - Key offerings
Exhibit 102: Bausch Health Companies Inc. - Segment focus
12.4 BIAL
Exhibit 103: BIAL - Overview
Exhibit 104: BIAL - Product/Service
Exhibit 105: BIAL - Key offerings
12.5 Dr Reddys Laboratories Ltd.
Exhibit 106: Dr Reddys Laboratories Ltd. - Overview
Exhibit 107: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 108: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 109: Dr Reddys Laboratories Ltd. - Segment focus
12.6 Eisai Co. Ltd.
Exhibit 110: Eisai Co. Ltd. - Overview
Exhibit 111: Eisai Co. Ltd. - Business segments
Exhibit 112: Eisai Co. Ltd. - Key offerings
Exhibit 113: Eisai Co. Ltd. - Segment focus
12.7 GlaxoSmithKline Plc
Exhibit 114: GlaxoSmithKline Plc - Overview
Exhibit 115: GlaxoSmithKline Plc - Business segments
Exhibit 116: GlaxoSmithKline Plc - Key news
Exhibit 117: GlaxoSmithKline Plc - Key offerings
Exhibit 118: GlaxoSmithKline Plc - Segment focus
12.8 H Lundbeck AS
Exhibit 119: H Lundbeck AS - Overview
Exhibit 120: H Lundbeck AS - Product/Service
Exhibit 121: H Lundbeck AS - Key offerings
12.9 Johnson and Johnson
Exhibit 122: Johnson and Johnson - Overview
Exhibit 123: Johnson and Johnson - Business segments
Exhibit 124: Johnson and Johnson - Key news
Exhibit 125: Johnson and Johnson - Key offerings
Exhibit 126: Johnson and Johnson - Segment focus
12.10 Novartis AG
Exhibit 127: Novartis AG - Overview
Exhibit 128: Novartis AG - Business segments
Exhibit 129: Novartis AG - Key offerings
Exhibit 130: Novartis AG - Segment focus
12.11 Pfizer Inc.
Exhibit 131: Pfizer Inc. - Overview
Exhibit 132: Pfizer Inc. - Product/Service
Exhibit 133: Pfizer Inc. - Key news
Exhibit 134: Pfizer Inc. - Key offerings
12.12 Sanofi SA
Exhibit 135: Sanofi SA - Overview
Exhibit 136: Sanofi SA - Business segments
Exhibit 137: Sanofi SA - Key news
Exhibit 138: Sanofi SA - Key offerings
Exhibit 139: Sanofi SA - Segment focus
12.13 SK Inc.
Exhibit 140: SK Inc. - Overview
Exhibit 141: SK Inc. - Product/Service
Exhibit 142: SK Inc. - Key offerings
12.14 Sumitomo Pharma Co. Ltd.
Exhibit 143: Sumitomo Pharma Co. Ltd. - Overview
Exhibit 144: Sumitomo Pharma Co. Ltd. - Business segments
Exhibit 145: Sumitomo Pharma Co. Ltd. - Key offerings
Exhibit 146: Sumitomo Pharma Co. Ltd. - Segment focus
12.15 Sun Pharmaceutical Industries Ltd.
Exhibit 147: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 148: Sun Pharmaceutical Industries Ltd. - Product/Service
Exhibit 149: Sun Pharmaceutical Industries Ltd. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 150: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 151: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 152: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 153: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 154: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 UCB SA
Exhibit 155: UCB SA - Overview
Exhibit 156: UCB SA - Product/Service
Exhibit 157: UCB SA - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 158: Inclusions checklist
Exhibit 159: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 160: Currency conversion rates for US$
13.4 Research methodology
Exhibit 161: Research methodology
Exhibit 162: Validation techniques employed for market sizing
Exhibit 163: Information sources
13.5 List of abbreviations
Exhibit 164: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Country Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 6: Executive Summary - Chart on Market Segmentation by Product
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on APAC - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on APAC: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Regional - Market size and forecast 2023-2028 ($ million)
Exhibits 18: Historic Market Size - Data Table on epilepsy therapeutics market in APAC 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Product Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Five forces analysis - Comparison between 2023 and 2028
Exhibits 23: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 24: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 25: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 28: Chart on Market condition - Five forces 2023 and 2028
Exhibits 29: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 30: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 31: Chart on Comparison by Distribution Channel
Exhibits 32: Data Table on Comparison by Distribution Channel
Exhibits 33: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 34: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 36: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 37: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 38: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 40: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 41: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 42: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
Exhibits 43: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 44: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
Exhibits 45: Market opportunity by Distribution Channel ($ million)
Exhibits 46: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 47: Chart on Product - Market share 2023-2028 (%)
Exhibits 48: Data Table on Product - Market share 2023-2028 (%)
Exhibits 49: Chart on Comparison by Product
Exhibits 50: Data Table on Comparison by Product
Exhibits 51: Chart on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibits 52: Data Table on First-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Chart on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibits 54: Data Table on First-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibits 55: Chart on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibits 56: Data Table on Second-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Chart on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibits 58: Data Table on Second-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibits 59: Chart on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibits 60: Data Table on Third-generation epilepsy therapeutics - Market size and forecast 2023-2028 ($ million)
Exhibits 61: Chart on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibits 62: Data Table on Third-generation epilepsy therapeutics - Year-over-year growth 2023-2028 (%)
Exhibits 63: Market opportunity by Product ($ million)
Exhibits 64: Data Table on Market opportunity by Product ($ million)
Exhibits 65: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 66: Chart on Market share By Geographical Landscape - 2023-2028 (%)
Exhibits 67: Data Table on Market share By Geographical Landscape - 2023-2028 (%)
Exhibits 68: Chart on Geographic comparison
Exhibits 69: Data Table on Geographic comparison
Exhibits 70: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 71: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 73: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 74: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 75: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 77: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 78: Chart on India - Market size and forecast 2023-2028 ($ million)
Exhibits 79: Data Table on India - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibits 81: Data Table on India - Year-over-year growth 2023-2028 (%)
Exhibits 82: Chart on Australia - Market size and forecast 2023-2028 ($ million)
Exhibits 83: Data Table on Australia - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Chart on Australia - Year-over-year growth 2023-2028 (%)
Exhibits 85: Data Table on Australia - Year-over-year growth 2023-2028 (%)
Exhibits 86: Chart on Rest of APAC - Market size and forecast 2023-2028 ($ million)
Exhibits 87: Data Table on Rest of APAC - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Chart on Rest of APAC - Year-over-year growth 2023-2028 (%)
Exhibits 89: Data Table on Rest of APAC - Year-over-year growth 2023-2028 (%)
Exhibits 90: Market opportunity By Geographical Landscape ($ million)
Exhibits 91: Data Table on Market opportunity By Geographical Landscape ($ million)
Exhibits 92: Impact of drivers and challenges in 2023 and 2028
Exhibits 93: Overview on Criticality of inputs and Factors of differentiation
Exhibits 94: Overview on factors of disruption
Exhibits 95: Impact of key risks on business
Exhibits 96: Vendors covered
Exhibits 97: Matrix on vendor position and classification
Exhibits 98: Bausch Health Companies Inc. - Overview
Exhibits 99: Bausch Health Companies Inc. - Business segments
Exhibits 100: Bausch Health Companies Inc. - Key news
Exhibits 101: Bausch Health Companies Inc. - Key offerings
Exhibits 102: Bausch Health Companies Inc. - Segment focus
Exhibits 103: BIAL - Overview
Exhibits 104: BIAL - Product/Service
Exhibits 105: BIAL - Key offerings
Exhibits 106: Dr Reddys Laboratories Ltd. - Overview
Exhibits 107: Dr Reddys Laboratories Ltd. - Business segments
Exhibits 108: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits 109: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits 110: Eisai Co. Ltd. - Overview
Exhibits 111: Eisai Co. Ltd. - Business segments
Exhibits 112: Eisai Co. Ltd. - Key offerings
Exhibits 113: Eisai Co. Ltd. - Segment focus
Exhibits 114: GlaxoSmithKline Plc - Overview
Exhibits 115: GlaxoSmithKline Plc - Business segments
Exhibits 116: GlaxoSmithKline Plc - Key news
Exhibits 117: GlaxoSmithKline Plc - Key offerings
Exhibits 118: GlaxoSmithKline Plc - Segment focus
Exhibits 119: H Lundbeck AS - Overview
Exhibits 120: H Lundbeck AS - Product/Service
Exhibits 121: H Lundbeck AS - Key offerings
Exhibits 122: Johnson and Johnson - Overview
Exhibits 123: Johnson and Johnson - Business segments
Exhibits 124: Johnson and Johnson - Key news
Exhibits 125: Johnson and Johnson - Key offerings
Exhibits 126: Johnson and Johnson - Segment focus
Exhibits 127: Novartis AG - Overview
Exhibits 128: Novartis AG - Business segments
Exhibits 129: Novartis AG - Key offerings
Exhibits 130: Novartis AG - Segment focus
Exhibits 131: Pfizer Inc. - Overview
Exhibits 132: Pfizer Inc. - Product/Service
Exhibits 133: Pfizer Inc. - Key news
Exhibits 134: Pfizer Inc. - Key offerings
Exhibits 135: Sanofi SA - Overview
Exhibits 136: Sanofi SA - Business segments
Exhibits 137: Sanofi SA - Key news
Exhibits 138: Sanofi SA - Key offerings
Exhibits 139: Sanofi SA - Segment focus
Exhibits 140: SK Inc. - Overview
Exhibits 141: SK Inc. - Product/Service
Exhibits 142: SK Inc. - Key offerings
Exhibits 143: Sumitomo Pharma Co. Ltd. - Overview
Exhibits 144: Sumitomo Pharma Co. Ltd. - Business segments
Exhibits 145: Sumitomo Pharma Co. Ltd. - Key offerings
Exhibits 146: Sumitomo Pharma Co. Ltd. - Segment focus
Exhibits 147: Sun Pharmaceutical Industries Ltd. - Overview
Exhibits 148: Sun Pharmaceutical Industries Ltd. - Product/Service
Exhibits 149: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibits 150: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 151: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 152: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 153: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 154: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 155: UCB SA - Overview
Exhibits 156: UCB SA - Product/Service
Exhibits 157: UCB SA - Key offerings
Exhibits 158: Inclusions checklist
Exhibits 159: Exclusions checklist
Exhibits 160: Currency conversion rates for US$
Exhibits 161: Research methodology
Exhibits 162: Validation techniques employed for market sizing
Exhibits 163: Information sources
Exhibits 164: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the epilepsy therapeutic market in APAC: Alkem Laboratories Ltd., Bausch Health Companies Inc., BIAL, Dr Reddys Laboratories Ltd., Eisai Co. Ltd., H Lundbeck AS, Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, SK Inc., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and GlaxoSmithKline Plc.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is reformation of marketed epilepsy drugs.'

According to the report, one of the major drivers for this market is the high unmet need for disease-modifying treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alkem Laboratories Ltd.
  • Bausch Health Companies Inc.
  • BIAL
  • Dr Reddys Laboratories Ltd.
  • Eisai Co. Ltd.
  • H Lundbeck AS
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SK Inc.
  • Sumitomo Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • GlaxoSmithKline Plc